ARGENTA
27.6.2022 09:01:10 CEST | Business Wire | Press release
Argenta today announced that Paul Fry will join the company as its new Chief Financial Officer, starting immediately. To ensure a smooth transition, Paul will work closely with former CFO Chris O’Donnell until late August.
The CFO role is being relocated from New Zealand to London to enable the CEO and CFO to work closely together in the same time zone, and to be closer to customers and new commercial opportunities.
Chris O’Donnell, who has served as Argenta’s CFO since 2018, is supportive of the decision and has decided to stay in New Zealand. He stepped down from his role on June 24 and will stay on until August 26 to support with the transition. Chris has played a leading role in the success and growth of Argenta, providing skilful oversight to key projects including the transition of ownership to KKR and the acquisition of Klifovet.
Paul Fry has extensive financial experience across several industries including biotech, pharmaceuticals, and telecommunications. Prior to joining Argenta, he was Chief Financial Officer of Vectura Group plc, an industry-leading inhaled drug delivery specialist which was listed on the main market of the London Stock Exchange until 2021. In his time with the company, he played an instrumental role in almost doubling its market valuation.
Before Vectura, Paul was Chief Financial Officer of Immunocore Limited, a leading biotech company focused on the development of a new class of immunotherapeutic drugs based on proprietary T-cell receptor (TCR) technology. He also served as Director of Global Finance Operations at Vodafone plc and spent more than 25 years at GSK, where he held several senior leadership roles.
Will Downie, CEO of Argenta, said: “I am delighted to welcome Paul to Argenta. His proven track record and extensive experience, combined with his strategic financial expertise and outstanding leadership qualities, will have a significant impact on the company. I am excited to partner with Paul to help drive long-term growth and scale for the organization.
“I would also like to take this opportunity to express my gratitude to Chris O’Donnell for his commitment, partnership, and financial stewardship in the time we have worked together. Chris has helped to lay the solid foundation that supports the company's ambitious strategy.”
Paul Fry said: “It is an exciting time to enter the animal health industry and I am delighted to be joining Argenta. The company has a unique offering, strong track record and the potential for significant growth for many years to come. I feel privileged to be able to contribute to this and to have the opportunity to serve Argenta’s customers, team members and shareholders.”
Paul holds a degree from Oxford University and is a member of the Chartered Institute of Management Accounts. He is also a Non-executive Director and Chair of the Audit Committee at Avacta plc, an AIM-listed biotech company developing diagnostics and new oncology therapies.
About Argenta
Argenta is the only combined global Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) dedicated to animal health. Founded in 2006 in New Zealand, Argenta’s talented, diverse, and committed employees are driven to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States, the United Kingdom, and Germany, Argenta operates from ‘Molecule to Market’ in partnership with its customers to support their R&D, regulatory, clinical research, and manufacturing needs along the veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220626005001/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom